No abstract available
MeSH terms
-
Atherosclerosis* / drug therapy
-
Cyproheptadine / analogs & derivatives
-
Double-Blind Method
-
Humans
-
T-Lymphocytes*
Substances
-
rupatadine
-
Cyproheptadine
Grants and funding
Funding This work was funded by the European Community's Seventh Framework Programme (FP7/2012–2017) RiskyCAD, grant no. 305739 (G.C.), “Post-Doctoral Fellowship 2021” by “Fondazione Umberto Veronesi” 2021-442 (F.B.), PRIN 2017K55HLC (G.D.N.), and by grants from MIUR Progetto Eccellenza.